Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6252W HIGH $8.01
Volume
30.03 K
Value Traded
45.15 K
Short % Float
0.4%
Days to Cover
1.0
0%Week
-1.96%1 Month
-3.85%3 Month
+57.51%6 Month
-76.95%5 Year
-76.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
71.09 M
EPS (TTM)
-0.21
P/E Ratio
-
Ent. Value
55.74 M
Total Shares
47.39 M
Float Shares
7.70 M
Insiders
74.09%
Institutions
0.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ZYBT Catalyst Timeline
Dated clinical, regulatory and corporate events for Zhengye Biotechnology Holding Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zhengye Biotechnology Holding Limited
4Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 3
●Quarterly UpdateCorporate
Zhengye reports unaudited financial results for first six months of fiscal year 2026
▼Stock ListingCorporate
Nasdaq notification of bid price deficiency for Class A ordinary shares
Past FDA Catalysts and PDUFA Decisions
How ZYBT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ZYBT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in ZYBT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ZYBT for Q2 2026. | ||||
Ownership Trends
ZYBT Short Interest
Shares sold short, counted twice a month.
0.4%
Short % of Float
of tradable shares sold short
31.2K
Shares Sold Short
-53.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
70.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZYBT ranks across every disease it competes in
Competitive Position is a premium feature
See how ZYBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZYBT News
ZYBT▼ -1.3%today
Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
Zhengye Biotechnology Holding Limited reported its financial results for the first half of fiscal year 2026. Net revenue fell to RMB50.9 million, an 18.3% decrease from the previous year. Despite this, the company improved its gross profit margin to 32.9% and reduced its operating loss by 27.9%. The company aims to enhance profitability and expand into new markets.
Read more →ZYBT▼ -11.4%on this news· ran to -32% by day 3
Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement
Zhengye Biotechnology Holding Limited has regained compliance with Nasdaq's minimum bid price requirement. The company received a Compliance Letter on August 5, 2026, confirming that its Class A ordinary shares have met the $1.00 per share threshold for the last 10 consecutive business days. Zhengye remains listed on the Nasdaq Capital Market under the ticker ZYBT.
Read more →ZYBT▼ -64.4%on this news· ran to -83% by day 1
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
Zhengye Biotechnology Holding Limited has addressed unusual trading activity in its Class A ordinary shares, stating it is not aware of any material non-public information that would explain the increase. The company reassures that its operations are ongoing as usual and has been in contact with Nasdaq regarding the situation. Shareholders are advised to rely on official filings for information.
Read more →ZYBTZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Zhengye Biotechnology Holding Limited received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company has until November 25, 2026, to meet the requirement by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Despite this, the company's operations remain unaffected, and it is considering options to regain compliance.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
Zhengye Biotechnology Holding Limited reported its financial results for FY 2025, showing a significant decline in net revenue and gross profit compared to FY 2024. Despite challenges in the swine vaccine market and a net loss of RMB83.0 million, the company noted growth in its other vaccine segments and achieved several regulatory milestones. The company remains focused on long-term growth strategies and international market expansion.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
Zhengye Biotechnology Holding Limited announced the approval of a dual-class share structure at its annual general meeting on March 24, 2026. Effective April 7, 2026, Class A ordinary shares will trade on Nasdaq under the ticker ZYBT. This structure includes 1.9 billion Class A shares and 100 million Class B shares, enhancing shareholder voting rights.
Read more →ZYBTZhengye Biotechnology Holding Limited Notice of 2026 Annual General Meeting of Shareholders
Zhengye Biotechnology Holding Limited has announced its 2026 Annual General Meeting (AGM) scheduled for March 24, 2026, at 8:00 a.m. ET. The meeting will take place at the Jilin Economic & Technical Development Zone in China, with options for virtual participation via webcast. Shareholders eligible to vote must be on record by February 12, 2026, and the board recommends approval of several key proposals, including the election of directors and share reclassification.
Read more →ZYBTZhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders
Zhengye Biotechnology Holding Limited announced its 2026 Chairman’s Letter to shareholders on February 10, 2026. The company secured three new veterinary drug registration certificates and four patent grants in 2025. It also established commercial relationships with 40% of large-scale swine enterprises. These developments support the firm's strategic growth priorities for the coming year.
Read more →ZYBTZHENGYE BIOTECHNOLOGY HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of RMB and US$, except for number of shares) As of
Zhengye Biotechnology Holding Limited reported its unaudited condensed consolidated financial statements, revealing significant losses. For the six months ending June 30, 2025, the company experienced a net loss of 25,550 RMB, which marks a deterioration compared to the previous period. Operating income also declined sharply, and comprehensive income reflects ongoing operational challenges and financial instability. The assets and liabilities indicate a complex financial situation, necessitating strategic reconsideration for the future.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
Zhengye Biotechnology Holding Limited reported its fiscal year 2024 financial results, revealing a 12% decrease in net revenues to RMB 186.4 million. The company is strategically diversifying its customer base by reducing swine vaccine sales to mitigate risks. Despite challenges, Zhengye continues to invest in R&D and has made strides in the pet vaccine market, receiving two important veterinary drug certifications.
Read more →ZYBT▼ -12.3%on this news
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F
Zhengye Biotechnology Holding Limited has received a Delinquency Letter from NASDAQ due to its late filing of the annual Form 20-F for the fiscal year ending December 31, 2024. The notice states that the company is not in compliance with NASDAQ Listing Rule 5250(c)(1). Zhengye has 60 days to submit a Compliance Plan to regain compliance and may receive a 180-day extension if the plan is accepted. Despite the notice, the letter does not have an immediate adverse impact on the listing of the company's shares.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option
Zhengye Biotechnology Holding Limited announced the full exercise of the underwriters' over-allotment option related to its recent initial public offering. This decision led to the purchase of an additional 225,000 ordinary shares at $4.00 each, increasing the total gross proceeds to $6.9 million. The funds will be allocated towards acquiring vaccine production companies and conducting research and development projects. The company's products, with a focus on veterinary vaccines for livestock, are already present in various regions across China and export markets.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering
Zhengye Biotechnology Holding Limited has announced the pricing of its initial public offering (IPO) of 1,500,000 ordinary shares at $4.00 per share. The shares have been approved for trading on the Nasdaq Capital Market under the ticker symbol 'ZYBT' and are expected to begin trading on January 7, 2025. The company anticipates gross proceeds of $6 million from the offering, which will be utilized for acquisitions and research and development in veterinary vaccines. The offering is set to close around January 8, 2025, pending regulatory approvals.
Read more →About Zhengye Biotechnology Holding Limited
BIOPHARMAWATCH ELITE
Trade the next ZYBT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime